 | |
| Names | |
|---|---|
| IUPAC name (E)-3-ethyl-5-(2-ethylbutyl)-4-hydroxy-6-(pent-2-en-3-yl)-2H-pyran-2-one | |
| Identifiers | |
| 3D model (JSmol) | |
InChI
| |
SMILES
| |
| Properties | |
| Chemical formula | C18H28O3 |
| Molar mass | 292.419 g·mol |
| Appearance | Pale yellow oil |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references | |
Prescopranone is a key intermediate in the biosynthesis of scopranones. Prescopranone is the precursor to scopranone A, scopranone B, and scopranone C, which are produced by Streptomyces sp. BYK-11038.
Biosynthesis
The biosynthesis of prescopranone follows the module structure of a Type I polyketide synthase (PKS) with three elongation modules and a lactonizing thioesterase domain. Genome mining of Streptomyces sp. BYK identified a scopranone biosynthetic gene cluster containing 3 genes, sprA, sprB, and sprC, that encode modular PKSs.
A starter acyl carrier protein is loaded with malonyl-CoA, and decarboxylated by a ketosynthase (KS). The starter unit is then transferred to module 1, which elongates the polyketide chain with ethyl malonyl-CoA. The tailoring domain of this module reduces the β-carbonyl to an alkene. Module 2 elongates the polyketide with ethylbutyl-malonyl-CoA. Finally, module 3 elongates the polyketide chain with ethyl malonyl-CoA, and is released upon the lactonization of the polyketide product by a thioesterase domain. Following the cyclization and release of the polyketide, the product undergoes a keto-enol tautomerism to form prescopranone. Both modules 2 and 3 contain dysfunctional ketoreductase (KR) domains, which do not reduce the β-carbonyl due to missing NAD(P)H binding motifs and tyrosine residues in their active sites. Prescopranone undergoes post-PKS transformations to form scopranones. Additionally, the deletion of a downstream gene sprT can disrupt biosynthesis of scopranones in Streptomyces avermitilis SUKA54. The products of this mutated pathway have yet to be elucidated.
Research
Prescopranone and similar compounds are currently being investigated as bone morphogenetic protein (BMP) inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP).
References
- Uchida, R, Lee, D, Suwa, I, Ohtawa, M, Watanabe, N, Demachi, A, Ohte, S, Katagiri, T, Nagamitsu, T, Tomoda, H (2017). "Scopranones with Two Atypical Scooplike Moieties Produced by Streptomyces sp. BYK-11038". Org. Lett. 19 (21): 5980–5983. doi:10.1021/acs.orglett.7b03003. PMID 29063763.
- ^ Demach, i A, Uchida, R, Arima, S, Nagamitsu, T, Hashimoto, J, Komatsu, M, Kozone, I, Shin-ya, K, Tomoda, H, Ikeda, H (2019). "An Unusual Extender Unit Is Incorporated into the Modular Polyketide Synthase of Scopranones Biosynthesis". Biochemistry. 58 (50): 5066–5073. doi:10.1021/acs.biochem.9b00908. PMID 31756295. S2CID 208234758.
- ^ Demachi, A, Ohte, S, Uchida, R, Shin-Ya, K, Ohshiro, T, Tomoda, H, Ikeda, H (2022). "Discovery of prescopranone, a key intermediate in scopranone biosynthesis". The Journal of Antibiotics. 75 (6): 305–311. doi:10.1038/s41429-022-00521-x. PMID 35444295. S2CID 248298343.